The importance of circulating tumor products as „liquid biopsies” in colorectal cancer [PDF]
Journal of Mind and Medical Sciences, 2018 Liquid biopsies represent an array of plasma analysis tests that are studied to evaluate and identify circulating tumor products, especially circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA).
Alina Miscoci +6 more
doaj +4 more sources
The rationale for liquid biopsy in colorectal cancer: focus on circulating tumor cells [PDF]
, 2015 Capturing circulating tumor cells (CTCs) and/or circulating tumor DNA from blood, which represents a precious source of biological material derived from both primary and metastatic tumors, has been named a 'liquid biopsy'. While the circulating tumor DNA
Carletti, Raffaella +6 more
core +1 more source
Next Generation Sequencing Assay for Detection of Circulating HPV DNA (cHPV-DNA) in Patients Undergoing Radical (Chemo)Radiotherapy in Anal Squamous Cell Carcinoma (ASCC). [PDF]
, 2020 Background: Following chemo-radiotherapy (CRT) for human papilloma virus positive (HPV+) anal squamous cell carcinoma (ASCC), detection of residual/recurrent disease is challenging.
Augustin, Y +10 more
core +3 more sources
What information could the main actors of liquid biopsy provide? A representative case of non-small cell lung cancer (NSCLC) [PDF]
, 2018 In non-small cell lung cancer (NSCLC), there is a consensus regarding the use of liquid biopsy, generally, to detect "druggable" mutations and, in particular, to monitor tyrosine kinase inhibitor (TKI) treatments. However, whether circulating tumor cells
Manicone, M. +6 more
core +1 more source
ctDNA and CTCs in Liquid Biopsy – Current Status and Where We Need to Progress
Computational and Structural Biotechnology Journal, 2018 We discuss the current status of liquid biopsy and its advantages and challenges with a focus on pre-analytical sample handling, technologies and workflows. The potential of circulating tumor cells and circulating tumor DNA is pointed out and an overview
Martin H.D. Neumann +3 more
doaj +1 more source
Clinical correlates of circulating cell-free DNA tumor fraction.
PLoS ONE, 2021 BackgroundOncology applications of cell-free DNA analysis are often limited by the amount of circulating tumor DNA and the fraction of cell-free DNA derived from tumor cells in a blood sample.
Joerg Bredno +4 more
doaj +1 more source
Circulating Cell-Free DNA in Dogs with Mammary Tumors: Short and Long Fragments and Integrity Index [PDF]
, 2017 Circulating cell-free DNA (cfDNA) has been considered an interesting diagnostic/prognostic plasma biomarker in tumor-bearing subjects. In cancer patients, cfDNA can hypothetically derive from tumor necrosis/apoptosis, lysed circulating cells, and some ...
A Asmarinah +79 more
core +6 more sources
Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy. [PDF]
, 2017 Current cell-free DNA (cfDNA) next generation sequencing (NGS) precision oncology workflows are typically limited to targeted and/or disease-specific applications.
Alva, Ajjai S +31 more
core +1 more source
Circulating tumor DNA as prognostic markers for late stage NSCLC with bone metastasis
The International Journal of Biological Markers, 2018 Purpose: Bone metastases from non-small cell lung cancer (NSCLC) are common, and current prognostic stratification methods are challenging to predict outcomes.
Jiguang Jia +3 more
doaj +1 more source
Salivary Biomarkers for Oral Squamous Cell Carcinoma Diagnosis and Follow-Up: Current Status and Perspectives [PDF]
, 2019 Oral cancer is the sixth most common cancer type in the world, and 90% of it is represented by oral squamous cell carcinoma (OSCC). Despite progress in preventive and therapeutic strategies, delay in OSCC diagnosis remains one of the major causes of high
Campisi, Giuseppina +5 more
core +1 more source